For the Inventor, By the Inventor

Enter assignee name

Richmond, CA, United States of America

Berlex Laboratories, Inc.

USPTO Granted Patents = 100

% Expired Patents = 15.0

Forward Citations = 1,938

Loading Chart...

Loading Chart...

99 inventors (with patents filed for the assignee):

Michael M Morrissey (49 out of 73 patents)

Gary Bruce Phillips (31 out of 81 patents)

Howard P Ng (25 out of 76 patents)

4. David D Davey (23 out of 43 patents)

5. Raju Mohan (18 out of 77 patents)

6. Brad Owen Buckman (17 out of 47 patents)

7. Monica J Kochanny (17 out of 27 patents)

8. Shung C Wu (15 out of 29 patents)

9. William J Guilford (13 out of 39 patents)

10. Wei Xu (12 out of 81 patents)

11. Zuchun Zhao (12 out of 39 patents)

12. Damian O Arnaiz (11 out of 23 patents)

13. Bin Ye (10 out of 22 patents)

14. Kenneth Jay Shaw (9 out of 19 patents)

15. James J Devlin (7 out of 39 patents)

Core Competencies:

Anti-Coagulants

Benzamidine Derivatives

N-Heterocyclic Derivatives

Polyhydroxylated Compounds

Aryl Substituted Pyrimidines

Thio Acid Derivatives

Somatostatin Analogs

Scintigraphic Imaging Agents

Chronic Muscle Pain Treatment

Ultra-Low Dose Therapies

Interferon Production

Chemical Reaction Apparatus

100 patents: Sort by Forward Citations

1. 6887865 - N-heterocyclic derivatives as NOS inhibitors (2005-05-03),

2. 6884418 - Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy (2005-04-26),

3. 6864368 - N-heterocyclic derivatives as NOS inhibitors (2005-03-08),

4. 6864263 - N-heterocyclic derivatives as NOS inhibitors (2005-03-08),

5. 6849739 - N-heterocyclic derivatives as NOS inhibitors (2005-02-01),

6. 6846829 - N-heterocyclic derivatives as NOS inhibitors (2005-01-25),

7. 6841674 - N-heterocyclic derivatives as NOS inhibitors (2005-01-11),

8. 6841673 - N-heterocyclic derivatives as nos inhibitors (2005-01-11),

9. 6686367 - Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants (2004-02-03),

10. 6686364 - Benzamidine derivatives and their use as anti-coagulants (2004-02-03),

11. 6559147 - Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants (2003-05-06),

12. 6552030 - Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants (2003-04-22),

13. 6498185 - Ortho-anthranilamide derivatives as anti-coagulants (2002-12-24),

14. 6495684 - Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants (2002-12-17),

15. 6495574 - Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants (2002-12-17),

Company Overview

Berlex Laboratories, Inc., based in Richmond, California, specializes in the development and manufacturing of anti-coagulant compounds. The company focuses on innovative therapeutic solutions, particularly in the realm of benzamidine derivatives, N-heterocyclic derivatives, and polyhydroxylated compounds. Additionally, Berlex is engaged in research on aryl substituted pyrimidines, thio acid derivatives, somatostatin analogs, and scintigraphic imaging agents, contributing to advancements in medical treatments and diagnostics.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

100 Patents

#3 in Richmond, CA

#870 in California

#3,797 in US

#7,784 in the World

Richmond, CA, United States of America

Berlex Laboratories, Inc.

Forward Citations = 1,938

99 inventors:

Michael M Morrissey (49 out of 73 patents)

Gary Bruce Phillips (31 out of 81 patents)

Howard P Ng (25 out of 76 patents)

4. David D Davey (23 out of 43 patents)

5. Raju Mohan (18 out of 77 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Berlex Laboratories, Inc.. Retrieved from https://idiyas.com/company/berlex-laboratories

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…